CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
1.330
-0.120 (-8.28%)
At close: Nov 19, 2026, 4:00 PM EST
1.320
-0.010 (-0.75%)
After-hours: Nov 19, 2026, 7:55 PM EST
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes CervoMed the 39,173rd largest employer in the world and 5,690th in the United States.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$582
Profits / Employee
-$1,901,236
Market Cap
20.12M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Mar 31, 2023 | 4 | - | - |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 113 |
| IGC Pharma | 70 |
| BeyondSpring | 44 |
| Cue Biopharma | 29 |
| Aardvark Therapeutics | 28 |
| Filana Therapeutics | 20 |
| ABVC BioPharma | 19 |
| TransCode Therapeutics | 12 |
CRVO News
- 3 days ago - CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia - GlobeNewsWire
- 9 days ago - CervoMed price target lowered to $6 from $7 at Roth Capital - TheFly
- 10 days ago - CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 13 days ago - CervoMed Quarterly report: Q3 2026 - Filings
- 13 days ago - CervoMed Earnings release: Q3 2026 - Filings
- 21 days ago - CervoMed announces publication of two articles supporting neflamapimod - TheFly
- 21 days ago - CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 5 weeks ago - CervoMed presents initial data from neflamapimod trial - TheFly